SenzaGen AB (STO:SENZA)

Market Cap	158.73M
Revenue (ttm)	57.02M
Net Income (ttm)	-18.89M
Shares Out	29.50M
EPS (ttm)	-0.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,305
Average Volume	19,751
Open	5.24
Previous Close	5.36
Day's Range	5.20 - 5.44
52-Week Range	3.86 - 8.20
Beta	0.27
RSI	49.74
Earnings Date	Aug 20, 2025

About SenzaGen AB

SenzaGen AB provides non-animal tests for assessing allergenicity. The company offers GARD skin OECD 442E, GARD skin dose-response, GARD skin medical device; and GARD air, a respiratory sensitization assessment. It also provides biological evaluation, in vitro biocompatibility testing, cytotoxicity, irritation, and skin sensitization medical device services; advisory services for medical devices; and substance based medical devices. In addition, the company offers regulatory toxicity testing services, including skin corrosion, skin irritation, ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2010
• Employees: 34
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SENZA

Financial Performance

In 2024, SenzaGen AB's revenue was 57.70 million, an increase of 15.69% compared to the previous year's 49.87 million. Losses were -17.85 million, -19.22% less than in 2023.